Author/Authors :
Antonio M. Gotto Jr، نويسنده , , Eliot A. Brinton، نويسنده ,
Abstract :
Clinical data show that a 1% increase in serum concentrations of high-density lipoprotein cholesterol (HDL-C) can decrease cardiovascular risk by 2% to 3%. Therefore, mechanisms affecting the level and functionality of high-density lipoprotein (HDL) and its constituents are being investigated as targets for the rational development of drugs to prevent or treat cardiovascular disease. High-density lipoprotein-related research may also increase our understanding of the link between atherosclerosis and metabolic disorders. This report and update of the HDL Working Group discusses HDL metabolism and reverse cholesterol transport, impaired HDL as a marker and a cause of proatherogenic states, and experimental and current approaches to HDL-related therapy.
Keywords :
coronary heart disease , HDL-C , apolipoprotein , PPAR , LCAT , LDL-C , RCT , HL , apo , CHD , ABC-A1 , adenosine triphosphate binding cassette-A1 , CETP , cholesteryl ester transfer protein , FCR , fractional catabolic rate , high-density lipoprotein cholesterol , hepatic lipase , lecithin:cholesterol acyltransferase , low-density lipoprotein cholesterol , peroxisome proliferator activated receptor , reverse cholesterol transport , SR-B1 , scavenger receptor B1 , VLDL , very low-density lipoprotein
